Drugs / Technetium Tc 99m Tilmanocept
Technetium Tc 99m Tilmanocept
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Lymphoseek | — | 2014-11-19 | europa.eu ↗ |
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02589366 | Nov 2015 → Apr 2018 | endometrial cancer | University of California, San Diego | Terminated | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04511026 | Jan → Jun 2021 | endometrial cancer | Stanford University | Terminated | Missed primary |
| Phase 2 | NCT03405142 | Aug → Dec 2019 | head and neck squamous cell carcinoma | Eben Rosenthal | Completed | No outcome recorded |
| Phase 2 | NCT02857608 | Sep 2016 → Aug 2017 | anal squamous cell carcinoma | Cardinal Health 414, LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT01902953 | Mar 2013 → Jun 2016 | colon carcinoma, rectal carcinoma | Maimonides Medical Center | Completed | No outcome recorded |
| Phase 33 trials · 2 met primary | ||||||
| Phase 3 | NCT01106040 | Jun 2010 → Apr 2011 | breast cancer, melanoma | Navidea Biopharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00911326 | May 2009 → Aug 2013 | head and neck squamous cell carcinoma | Navidea Biopharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00671918 | Apr 2008 → Jun 2009 | breast cancer, melanoma | Navidea Biopharmaceuticals | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT04261179 | Mar 2020 → Feb 2021 | breast cancer, malignant tumor of neck, melanoma | Anna Cruceta | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02287675 Comparator | Jan 2015 → Jan 2017 | breast cancer | Kettering Health Network | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Technetium Tc 99m Tilmanocept | “Lymphoseek (Lymphoseek (Technetium Tc 99m Tilmanocept) is a radiotracer that accumulates in lymphatic tissue by binding to a mannose binding receptor” NCT01902953 ↗ |
| Known as | 1600 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108726 ↗ |
| Known as | \[Tc 99m\] DTPA Mannosyl Dextran | “Lymphoseek (Technetium Tc 99m diethylenetriaminepentaacetic acid mannosyl dextran, \[Tc 99m\] DTPA Mannosyl Dextran) is a radiotracer that accumulates in lymphatic tissue by...” NCT01106040 ↗ |
| Known as | Lymphoseek | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02857608 ↗ |
| Known as | Lymphoseek kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108726 ↗ |
| Known as | Tc-99m Tilmanocept (Lymphoseek) | “Tc-99m Tilmanocept (Lymphoseek)” NCT00911326 ↗ |
| Known as | Technetium (99mtc) tilmanocept | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108726 ↗ |
| Known as | Technetium Tc 99m diethylenetriaminepentaacetic acid mannosyl dextran | “Lymphoseek (Technetium Tc 99m diethylenetriaminepentaacetic acid mannosyl dextran, \[Tc 99m\] DTPA Mannosyl Dextran) is a radiotracer that accumulates in lymphatic tissue by...” NCT01106040 ↗ |
| Modality | Diagnostic / imaging agent | “[(99m)Tc]tilmanocept is a CD206 receptor-targeted radiopharmaceutical designed for sentinel lymph node (SLN) identification.” PMID 23054107 ↗ Oct 2012 |
| Route | Other | “intradermal administration of Lymphoseek” NCT00671918 ↗ |